{"product_id":"acaluni-acalabrutinib-2","title":"Acaluni (Acalabrutinib)   Акалуни (акалабрутиниб)","description":"Acalabrutinib is used to treat people with mantle cell lymphoma (MCL; a fast-growing cancer that begins in the cells of the immune system) who have already been treated with at least one other chemotherapy medication. It is also used alone or with obinutuzumab (Gazyva) to treat chronic lymphocytic leukemia (CLL; a type of cancer that begins in the white blood cells) and small lymphocytic lymphoma (SLL: a type of cancer that begins in the white blood cells). Acalabrutinib is in a class of medications called kinase inhibitors. It works by blocking the action of the abnormal protein that signals cancer cells to multiply. This helps stop the spread of cancer cells.\r\n\r\nADULT\r\n\u003ch3\u003eMantle Cell Lymphoma\u003c\/h3\u003e\r\nIndicated for mantle cell lymphoma (MCL) in patients who have received ≥1 prior therapy\r\n\r\n100 mg PO q12hr\r\n\r\nContinue until disease progression or unacceptable toxicity\r\n\u003ch3\u003eChronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma\u003c\/h3\u003e\r\nIndicated for treatment of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)\r\n\u003ch4\u003eMonotherapy\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003e100 mg PO q12hr\u003c\/li\u003e\r\n \t\u003cli\u003eContinue until disease progression or unacceptable toxicity\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003eCombination with obinutuzumab\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eIndicated for patients with previously untreated CLL or SLL\u003c\/li\u003e\r\n \t\u003cli\u003eStart acalabrutinib at Cycle 1 (each cycle is 28 days)\u003c\/li\u003e\r\n \t\u003cli\u003eStart obinutuzumab at Cycle 2 for a total of 6 cycles\u003c\/li\u003e\r\n \t\u003cli\u003eRefer to obinutuzumab for infusion rates\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch5\u003eCycle 1\u003c\/h5\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eDays 1-28: Acalabrutinib 100 mg PO q12hr\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch5\u003eCycle 2\u003c\/h5\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eDays 1-28: Acalabrutinib 100 mg PO q12hr\u003c\/li\u003e\r\n \t\u003cli\u003eDay 1: Obinutuzumab 100 mg IV infusion\u003c\/li\u003e\r\n \t\u003cli\u003eDay 2: Obinutuzumab 900 mg IV infusion\u003c\/li\u003e\r\n \t\u003cli\u003eDays 8 and 15: Obinutuzumab 1000 mg IV infusion\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch5\u003eCycles 3-7\u003c\/h5\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eDay 1-28: Acalabrutinib 100 mg PO q12hr\u003c\/li\u003e\r\n \t\u003cli\u003eDay 1: Obinutuzumab 1000 mg IV infusion\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch5\u003eCycle 8 and subsequent cycles\u003c\/h5\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eDay 1-28: Acalabrutinib 100 mg PO q12hr\u003c\/li\u003e\r\n \t\u003cli\u003eContinue until disease progression or unacceptable toxicity\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e","brand":"Tongmeng (Lao) Pharmaceutical \u0026 Food Co., Ltd.（TLPH）","offers":[{"title":"Default Title","offer_id":44797947805739,"sku":"RL14202309011310","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2023-04-2050.png?v=1787022102","url":"https:\/\/xomeds.com\/products\/acaluni-acalabrutinib-2","provider":"XOMEDS","version":"1.0","type":"link"}